Please assess the completion status of the following clinical trial:

Trial Title: (SGB) in Men Treated for Prostate Cancer Improve Hot Flashes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Men with prostate cancer (with or without metastatic disease) on ADT for at least 2 months~2. Age less than 65 years~3. Body Mass Index (BMI) less than 32~4. Willingness to undergo image guided intervention~5. Greater than 28 hot flashes per week.~Exclusion Criteria:~1. Conditions that preclude SGB or sham intervention (e.g., anatomic abnormalities of the anterior neck or cervical spine; metastatic disease in or near the cervical spine; goiter;cardiac/pulmonary compromise; sleep apnea; acute illness/infection; coagulopathy or bleeding disorder; allergic reactions/contraindications to a local anesthetic or contrast dye)~2. Current treatment of prostate cancer with radium or chemotherapy~3. Use of treatments in the past two months that can affect HF (e.g., testosterone or androgen supplementation) Note: SSRIs, serotonin norepinephrine uptake inhibitors, and membrane stabilizers will be allowed but must be on stable unchanged dose for at least 8 weeks)~4. Inability to write, speak, or read in English

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- .5% Bupivacaine (Type: EXPERIMENTAL): Guided right sided stelate ganglion block using .5% bupivacaine (5mLs)

Based on this trial design, predict the completion outcome and termination type (if applicable).